Home/Filings/4/0001062993-23-022638
4//SEC Filing

Menold Daniel 4

Accession 0001062993-23-022638

CIK 0001042074other

Filed

Dec 14, 7:00 PM ET

Accepted

Dec 15, 4:38 PM ET

Size

14.5 KB

Accession

0001062993-23-022638

Insider Transaction Report

Form 4
Period: 2023-12-15
Menold Daniel
Vice President, Finance
Transactions
  • Exercise/Conversion

    Common Stock

    2023-12-15$4.05/sh+10,000$40,50010,000 total
  • Sale

    Common Stock

    2023-12-15$21.98/sh10,000$219,8470 total
  • Exercise/Conversion

    Common Stock

    2023-12-15$8.43/sh+11,497$96,92011,497 total
  • Sale

    Common Stock

    2023-12-15$21.99/sh11,497$252,7990 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2023-12-1510,000145,109 total
    Exercise: $4.05Exp: 2030-05-14Common Stock (10,000 underlying)
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2023-12-1511,4970 total
    Exercise: $8.43Exp: 2029-01-28Common Stock (11,497 underlying)
Footnotes (5)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.67 to $22.33, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.70 to $22.33, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The shares subject to the option vest in 48 equal monthly installments commencing on January 31, 2020.
  • [F5]The shares subject to the option vest as to 1/4 of the underlying shares on January 1, 2020, and vest as to 1/48 of the underlying shares monthly thereafter.

Issuer

CymaBay Therapeutics, Inc.

CIK 0001042074

Entity typeother

Related Parties

1
  • filerCIK 0001705745

Filing Metadata

Form type
4
Filed
Dec 14, 7:00 PM ET
Accepted
Dec 15, 4:38 PM ET
Size
14.5 KB